GLP-1s are becoming a mainstay for weight loss and diabetes treatment, and the demand for this type of drug is high.
GLP-1 agonists are a class of medications that can help manage Type 2 diabetes and obesity.
There are other promising new weight-loss drugs in the works too. Injectables, such as retatrutide, CagriSema (cagrilintide and semaglutide), and MariTide (maridebart cafraglutide), are in more advanced clinical trials.
More than ten medications are already FDA approved for weight loss. Wegovy (injectable semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide) are some of the popular ones.
As of January 6, 2025 here is a list of approved and pending new GLP-1 agonists class of medications that can help manage Type 2 diabetes and obesity:
Ozempic (semaglutide)
Approved - A weekly injectable GLP-1 receptor agonist that helps regulate blood sugar and suppress appetite, promoting weight loss in addition to managing type 2 diabetes.
Mounjaro (tirzepatide)
Approved - A dual-action injectable targeting GLP-1 and GIP receptors. Approved for type 2 diabetes and showing significant weight-loss benefits, with pending approval for obesity treatment.
Wegovy (semaglutide)
Approved - An injectable GLP-1 receptor agonist approved for chronic weight management. It reduces appetite and caloric intake, leading to significant weight loss when combined with diet and exercise.
Trulicity (dulaglutide)
Approved - A weekly GLP-1 receptor agonist for managing type 2 diabetes that also supports moderate weight loss by regulating appetite and blood sugar.
Zepbound (tirzepatide)
Approved - A once-weekly injectable medication approved by the FDA in November 2023 for chronic weight management. It works as a dual GIP and GLP-1 receptor agonist, helping regulate appetite and blood sugar.
Qsymia (phentermine/topiramate)
Approved - A combination medication that suppresses appetite and enhances feelings of fullness. It is used alongside diet and exercise for chronic weight management.
Contrave (naltrexone/bupropion)
Approved - An oral medication combining an opioid antagonist and an antidepressant. It targets hunger and reward pathways to reduce cravings and control eating.
Saxenda (liraglutide)
Approved - A daily injectable GLP-1 receptor agonist that aids in weight loss by decreasing appetite and increasing feelings of fullness. Approved for chronic weight management in adults with obesity or weight-related conditions.
Orforglipron
Pending Approval - An experimental oral GLP-1 receptor agonist in clinical trials. It shows promise in promoting weight loss by mimicking incretin hormones that regulate appetite.
Retatrutide
Pending Approval - A triple-action injectable drug targeting GLP-1, GIP, and glucagon receptors. Early studies suggest it may offer significant weight loss benefits by influencing multiple metabolic pathways.
CagriSema (cagrilintide/semaglutide)
Pending Approval - A combination injectable medication in development, combining cagrilintide and semaglutide to enhance weight loss through appetite suppression.
Amycretin
Pending Approval - An experimental oral drug mimicking GLP-1 and amylin hormones to suppress appetite and control blood sugar. Early studies show up to 13% body weight reduction in three months.
Interested in learning more about these weight loss medications?
Schedule Your Virtual Consultation Today
Call Just Melt Med Spa at 212-447-1155
